CEMPRA, INC. (NASDAQ:CEMP) Files An 8-K Other Events
Item8.01 Other Events.
On December29, 2016, we issued a press release to report the
receipt of a complete response letter from the U.S. Food and Drug
Administration relating to our new drug applications for oral and
intravenous solithromycin for the treatment of community-acquired
bacterial pneumonia in adults.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
Item9.01. Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo. |
Description |
|
| 99.1 | Press release dated December29, 2016. |
About CEMPRA, INC. (NASDAQ:CEMP)
Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI). CEMPRA, INC. (NASDAQ:CEMP) Recent Trading Information
CEMPRA, INC. (NASDAQ:CEMP) closed its last trading session up +0.20 at 6.10 with 2,253,132 shares trading hands.
